ATRA Shareholders Sue Atara Biotherapeutics Over Securities Fraud
Investors in Atara Biotherapeutics face a critical decision point as a securities fraud lawsuit moves forward with a May 22, 2026 deadline for lead plaintiff nominations. Shareholders who purchased ATRA stock between May 2024 and January 2026 may be eligible to represent the class action case.
ATRA Shareholders Sue Atara Biotherapeutics Over Securities Fraud Read More »









